Medicare outsources lab pricing to a single nonprofit data broker

What it does

This bill rewrites how Medicare pays for clinical diagnostic laboratory tests by requiring CMS to contract with an independent nonprofit data entity to collect private insurance claims data (at least 50 billion claims from 50+ insurers) and use that data to set Medicare payment rates instead of relying solely on lab-reported data. The bill phases in this new data-collection system starting in 2027–2028, with fallback protections (CPI adjustments) if no data contract exists or data is unavailable. The stated goal is to improve accuracy and stability of lab test payment rates; the practical effect is to shift Medicare pricing away from lab self-reporting toward market-based private payor rates, potentially lowering payments for labs and raising transparency around how rates are calculated.

Why we flagged it

The bill's core mechanism is a structural shift in how CMS determines lab test payment rates—from lab-reported data to private claims data collected by a contracted nonprofit entity. This is a regulatory redesign, not a simple rate adjustment, and it centralizes pricing authority in a single data intermediary.

What the text implies

• A single nonprofit data entity becomes the de facto arbiter of Medicare lab pricing for 'widely available' tests; if that entity fails, is compromised, or loses its data contract, Medicare defaults to CPI-only adjustments, potentially freezing rates below market for years.
• Labs lose direct control over the data used to set their payment rates; private payor claims data may not reflect their actual costs, especially for rural, safety-net, or specialized labs serving lower-volume populations.

The full analysis lists 5 implications of this text.

Who stands to gain

Medicare program (reduced lab test payments); Private insurers (their claims data becomes the pricing benchmark, potentially validating their nego; The contracted nonprofit data entity (receives CMS contract and operational funding)